The Medicines and Healthcare products Regulatory Agency (MHRA) have revealed their new corporate plan for 2018-23. In it, they set out how they will achieve their primary goals, and also their strategies for the Agency’s longer-term aims and objectives. The agency also provide information on how well they achieved the goals set in the previous corporate plan for 2013-18.
The MHRA are pleased to report that they have been able to introduce the Early Access to Medicines Scheme (EAMS), providing drugs to patients in need before licence finalisation, they have actively worked with, and led, crucial EU processes in regulation of medicines and devices, and they have made progress in ”joining up key functions” internally, helping improve the efficient running of the Agency.
The Agency has identified challenges to its next 5 year plan, including Brexit and technical challenges, but also enablers, such as the leading position the MHRA plays on the world stage in regulation. On top of these, there are broader context issues to note, such as the need to continually approve the regulatory processes of the Agency.
With this in mind, the Agency has determined its strategic goals will once again fit into the categories defined for the 2013-18 plan, namely:
- “We will protect public health and promote patient safety by ensuring the safety, efficacy and quality of medicines and healthcare products including through enhanced partnerships in the UK and internationally
- We will support and enhance innovation and accelerate routes to market to benefit public health and be a magnet for life sciences
- We will deliver robust proactive integrated vigilance for medicines and healthcare products and improve the way we share information to achieve measurable public health benefit
- We will ensure the safe production and supply of medicines and healthcare products through enhanced systems and strong international partnerships
- We will be an exemplar of organisational excellence and efficiency”
Achieving these goals depends on a range of activities: creating and maintaining strategic partnerships in the UK and around the world, making better use of real world data in decision making, supporting innovation in life sciences, and upskilling staff to ensure adaptability and flexibility.